80 / 100

Dr. Yuan Ma | Biochemistry | Best Researcher Award

Dr. Yuan Ma, The Chinese University of Hong Kong ,China.

🔬 Dr. MA Yuan (Ph.D.) is a distinguished researcher in nucleic acid-based drug discovery and aptamer-based translational medicine. Currently a Research Assistant Professor at Hong Kong Baptist University, he has contributed extensively to targeted cancer therapies and precision medicine. With 35+ publications, multiple patents, and high-impact grants, his work advances innovative drug development. He also mentors Ph.D. and Master’s students, shaping the future of pharmaceutical sciences. His groundbreaking research continues to transform therapeutic strategies in oncology and molecular medicine. 🏆🔍

🌟 Professional Profile

🎓 Early Academic Pursuits

MA Yuan’s academic journey began at the School of Pharmaceutical Sciences, Peking University, where he earned a Bachelor of Science (2009-2013), specializing in organic chemistry, pharmacology, and pharmaceutical analysis. He continued his education at the Stake Key Laboratory of Natural and Biomimetic Drugs, Peking University, completing a Master of Science (2013-2015) with a focus on DNA synthesis, advanced medicinal chemistry, and tumor pharmacology. His Ph.D. (2015-2019) at the same institution delved into nucleic acid chemistry, advanced organic chemistry, and natural pharmaceutical chemistry, culminating in a thesis on the properties, biological activity, and mechanism of novel nucleoside (acid) lipid delivery of single-stranded oligonucleotides under the mentorship of Prof. Zhenjun Yang.

💼 Professional Endeavors

Dr. MA Yuan’s professional career spans prestigious institutions. Since 2022, he has been a Research Assistant Professor at the Institute for Precision Medicine and Innovative Drug, Hong Kong Baptist University, leading aptamer-based translational research and drug discovery. Previously, he was a Postdoctoral Research Fellow (2020-2022) at the same institution and an Associate Research Fellow (2019-2020) at Mengchao Hepatobiliary Hospital of Fujian Medical University, where he contributed to nucleic acid-based diagnosis and treatment of primary liver cancer.

🔬 Contributions and Research Focus On Biochemistry 

Dr. MA Yuan’s research primarily focuses on aptamer-based drug discovery, nucleic acid chemistry, and translational medicine. His expertise spans nucleic acid-based therapies, precision medicine, and advanced pharmaceutical formulations. He has supervised multiple postgraduate students, contributing to groundbreaking studies in triple-negative breast cancer, ovarian cancer therapy, and osteogenesis imperfecta.

🌍 Impact and Influence

Through his research, Dr. MA Yuan has secured major research grants exceeding HK$ 51 million from institutions such as the Research Grants Council and the National Natural Science Foundation of China. His work has contributed significantly to novel drug discoveries and advancements in precision medicine. He also holds three patents for innovations in nucleic acid drug delivery and targeted cancer treatments.

🏆 Awards and Honors

Dr. MA Yuan has received several prestigious awards and recognitions, including Orphan Drug and Rare Pediatric Disease Designations from the FDA for his contributions to osteogenesis imperfecta and gastric cancer treatments.

📚Academic Citations

Dr. MA Yuan has authored 35 peer-reviewed publications in esteemed journals, furthering knowledge in nucleic acid chemistry, aptamer-based therapies, and pharmacology. His work has been widely cited, reflecting its impact on biomedical research and pharmaceutical sciences.

  • Machine learning-powered, high-affinity modification strategies for aptamers
    Journal: Acta Materia Medica
    Year: 2025
    📚🤖

  • Peptide Aptamer–Paclitaxel Conjugates for Tumor Targeted Therapy
    Journal: Pharmaceutics
    Year: 2024
    💊🎯

  • Developing Stapled Aptamers with a Constrained Conformation for Osteogenesis Imperfect Therapeutics
    Journal: Journal of Medicinal Chemistry
    Year: 2024
    🧬💉

  • Targeting osteoblastic 11β-HSD1 to combat high-fat diet-induced bone loss and obesity
    Journal: Nature Communications
    Year: 2024
    🍔🦴

  • Aptamer Functionalized Hypoxia-potentiating Agent and Hypoxia-inducible Factor Inhibitor Combined with Hypoxia-activated Prodrug for Enhanced Tumor Therapy
    Journal: Cancer Letters
    Year: 2024
    Citations: Not Available
    🧬🦠

  • Advancing targeted combination chemotherapy in triple negative breast cancer: nucleolin aptamer-mediated controlled drug release
    Journal: Journal of Translational Medicine
    Year: 2024
    🎗️💪

  • Sclerostin inhibition in rare bone diseases
    Journal: Journal of Orthopaedic Translation
    Year: 2024
    🦵🦴

  • Small RNAs in Cancer Therapy
    Book Chapter: Interdisciplinary Cancer Research
    Year: 2024
    Citations: Not Available
    📖🧬

  • Aptamer AS411 interacts with the KRAS promoter/hnRNP A1 complex and shows increased potency against drug-resistant lung cancer
    Journal: RSC Medicinal Chemistry
    Year: 2024
    🚬💪

  • Design and synthesis of nucleotidyl lipids and their application in the targeted delivery of siG12D for pancreatic cancer therapy
    Journal: Biomedicine and Pharmacotherapy
    Year: 2024
    🍍🔬

  • Unique quinoline orientations shape the modified aptamer to sclerostin for enhanced binding affinity and bone anabolic potential
    Journal: Molecular Therapy – Nucleic Acids
    Year: 2024
    🦴🔬

  • The Modification Strategies for Enhancing the Metabolic Stabilities and Pharmacokinetics of Aptamer Drug Candidates
    Book Chapter: Drug Metabolism and Pharmacokinetics
    Year: 2024
    💊🧬

  • Intracellular sclerostin plays a vital role in tumor progression and metastasis in triple-negative breast cancer
    Journal: Cancer Research
    Year: 2024
    🧠🔬

  • A bimolecular modification strategy for developing long-lasting bone anabolic aptamer
    Journal: Molecular Therapy – Nucleic Acids
    Year: 2023
    🦴✨

Yuan Ma | Biochemistry | Best Researcher Award

You May Also Like